التفاصيل البيبلوغرافية
| العنوان: |
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia |
| المؤلفون: |
Wu, Jingjing, Fu, Jiaping, Zhang, Mingzhi, Liu, Delong |
| بيانات النشر: |
BioMed Central Ltd. |
| سنة النشر: |
2015 |
| المجموعة: |
BioMed Central |
| الوصف: |
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia. |
| نوع الوثيقة: |
review |
| اللغة: |
English |
| العلاقة: |
http://www.jhoonline.org/content/8/1/104Test |
| الإتاحة: |
http://www.jhoonline.org/content/8/1/104Test |
| حقوق: |
Copyright 2015 Wu et al. |
| رقم الانضمام: |
edsbas.D560D7A1 |
| قاعدة البيانات: |
BASE |
